Imugene Limited dosed first patient in VAXINIA Intratumoral Cohort 2

Imugene Limited (ASX: IMU) announced that it had advanced its Phase 1 Metastatic Advanced Solid Tumors study assessing the protection from the novel cancer-killing virus CF33-hNIS, with the first patient medicated with intratumoral cohort 2 of the test. This announcement was followed by the September announcement that the first patient had been dosed under the intravenous cohort 1 study.

This trial is named “A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST).” The trial is expected to run for around 24 months and is funded from previous budgets and resources.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au